Local view for "http://purl.org/linkedpolitics/eu/plenary/2002-10-22-Speech-2-035"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2002-10-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Medicinal products2
dcterms:Language	"en"^^xsd:language2
lpv:document identification number	"en.20021022.1.2-035"2
lpv:hasSubsequent	lp_eu:2002-10-22-Speech-2-0362
lpv:speaker	lp:Catherine Stihler2
lpv:spoken text	"Mr President, I would like to thank the rapporteurs and shadow rapporteurs for their work. As many colleagues have said, pharmaceutical products are like no other. We must guarantee that these products are all safe and effective. Therefore, on the debate on the centralised procedure, I believe we must have flexibility. We should not restrict choice but allow for choice and support flexibility between the two routes. On the renewal of authorisation, I oppose the Commission's proposal to remove five-year renewal of marketing authorisation and rely on enhanced pharmaco-vigilance to ensure product safety and, indeed, exclusivity. I think the compromise which has been reached is a fair one. I am delighted that the Committee on the Environment has rejected direct consumer advertising. We must be very clear that we all want patients to be informed. We all want patients to make informed decisions – no one can argue with this. But we cannot have what happens in the US, where the ten most advertised drugs are the ten best selling drugs. This is where the amendments adopted in committee requesting a report and the question of how information to patients is used and enhanced are so important. Information to patients from the industry varies from excellent approaches and partnership with patients to situations where some patient organisations are being accused of being mere fronts for the industry. We must get the balance right. We have an opportunity in the review to do this, to improve research, to secure jobs, to improve availability of products to patients and improve information given to patients. It is an exciting time, and I look forward to the review returning for second reading."@en1
lpv:spokenAs	unknown; Labour Party (1999-07-20--2004-07-19)3 member; Committee on the Environment, Public Health and Consumer Policy (2002-01-17--2004-07-19)3 member; PES (1999-07-20--2004-07-19)3 substitute; Temporary committee on foot and mouth disease (2002-01-17--2002-12-17)3 member; Delegation to the EU-Hungary Joint Parliamentary Committee (2002-02-06--2004-04-30)3 member; PECH (2002-01-17--2004-07-19)3
lpv:unclassifiedMetadata	"Stihler (PSE )."1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph